secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2023-01-12T23:59:59+00:00
Accession:  0001104659-23-003471
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 5.07, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE shareholders approve reverse stock split; receives $5M deferred payment; redeems preferred
--------------------------------------------------------------------------------

- Stockholders approved reverse stock split at ratio from 1:10 to 1:25; board to set effective date within one year.
- Series A Preferred redeemed for $360,000 on Jan 17, 2023; Certificate of Elimination to be filed.
- Received $5.0M deferred payment from Journey Medical per Asset Purchase Agreement; pro forma cash $35.9M as of Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465923003471/0001104659-23-003471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465923003471/tm233167d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-003471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer